1 Aier School of Ophthalmology, Central South University, Changsha 410083, China 2 Department of Glaucoma, Shengyang Aier Eye Hospital, Shenyang 110000, China
Objective: To evaluate the 24-hour efficacy of tafluprost on the reduction of intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). Methods: In this case-series study, a total of 43 eyes of 22 newly diagnosed patients with POAG and OHT from Shengyang Aier Eye Hospital were enrolled. All patients were trained to use an Icare HOME tonometer to measure IOP by themselves. For the certificated patients, aphysician used GAT to measure their IOP three times, and then the patients used Icare HOME to measure 24-hour IOP by themselves. Patients was given tafluprost once a day at 2100. Icare HOME was used by the patients themselves to measure 24-hour IOP again one month later. A one-way ANOVA and Bland-Altman analysis were used to compare the consistency of the GAT used by a physician and the Icare HOME used by patients to measure IOP. A paired t test was used to compare IOP at each time point, the mean, the peak, the valley and the fluctuation of 24-hour IOP before and after treatment with tafluprost. Results: The mean IOPs measured with GAT by a physician and Icare HOME by patients were 18.2±3.7 mmHg (1 mmHg=0.133 kPa) and 17.4±4.2 mmHg, respectively, with no statistically significant difference (F=0.837, P=0.363). Bland-Altman analysis showed that there was a good consistency between GAT measured by a physician and Icare HOME measured by patients. IOP decreased at all time points of assessment after 1 month (all P<0.05). The range of IOP reduction at different time points was 1.8 to 5.5 mmHg (all P<0.05). The mean, the peak, the valley, and the fluctuation of IOP at baseline were 19.4±5.0, 25.0±5.8, 14.1±4.5 and 10.9±3.8 mmHg, respectively, and were reduced to 15.6±4.2, 20.4±4.5, 11.3±3.6 and 9.2±2.9 mmHg after treatment (t=9.450, 9.636, 5.939, 3.137, all P<0.05). Conclusions: Tafluprost provides effective 24-hour IOP reduction in newly diagnosed patients with POAG and OHT.
Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol, 2010, 4: 163-170. DOI: 10.2147/OPTH.S6368.
[2]
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol, 2002, 120(6): 701-713, 829-830. DOI: 10.1001/archopht.120.6.701.
[3]
Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology, 2016, 123(1): 129-140. DOI: 10.1016/j.ophtha.2015.09.005.
Kuwayama Y, Nomura A. Prospective observational postmarketing study of tafluprost for glaucoma and ocular hypertension: Short-term efficacy and safety. Adv Ther, 2014, 31(4): 461-471. DOI: 10.1007/s12325-014-0109-9.
[7]
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol, 2002, 120(10): 1268-1279. DOI: 10.1001/archopht.120.10.1268.
Konstas AG, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol, 2013, 97(12): 1510-1515. DOI: 10.1136/bjophthalmol-2012-303026.
Mudie LI, LaBarre S, Varadaraj V, et al. The Icare HOME (TA022) Study: Performance of an intraocular pressure measuring device for self-tonometry by glaucoma patients. Ophthalmology, 2016, 123(8): 1675-1684. DOI: 10.1016/ j.ophtha.2016.04.044.
Takagi D, Sawada A, Yamamoto T. Evaluation of a new rebound self-tonometer, Icare HOME: Comparison With Goldmann Applanation Tonometer. J Glaucoma, 2017, 26(7): 613-618. DOI: 10.1097/IJG.0000000000000674.
[14]
Ota T, Aihara M, Saeki T, et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol, 2007, 91(5): 673-676. DOI: 10.1136/bjo.2006.105585.
[15]
Ota T, Murata H, Sugimoto E, et al. Prostaglandin analogues and mouse intraocular pressure: Effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci, 2005, 46(6): 2006-2011. DOI: 10.1167/iovs.04-1527.
[16]
Shin J, Lee J W, Choi BS, et al. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma. J Ocul Pharmacol Ther, 2014, 30(10): 803-809. DOI: 10.1089/ jop.2014.0034.
[17]
Cho SY, Kim YY, Yoo C, et al. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and bloodpressure monitoring. Jpn J Ophthalmol, 2016, 60(1): 27-34. DOI: 10.1007/s10384-015-0413-1.
[18]
Mochizuki H, Itakura H, Yokoyama T, et al. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Jpn J Ophthalmol, 2010, 54(4): 286-290. DOI: 10.1007/s10384-010-0828-7.
[19]
Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol, 2005, 139(2): 320-324. DOI: 10.1016/j.ajo.2004.09.062.
浙公网安备 33030202001892号